Skip to content
10-Q

Quarterly Report

BioRestorative Therapies, Inc. BRTX

0001641172-25-010299

← back to feed
Filed
May 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 13, 2025 7.5M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $1.23M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $547.89K
Current Liabilities Q1 2025 · Mar 31, 2025 $4.18M
Current Liabilities Q1 2025 · Dec 31, 2024 $3.75M
Total Liabilities Q1 2025 · Mar 31, 2025 $4.18M
Total Liabilities Q1 2025 · Dec 31, 2024 $3.75M
Current Assets Q1 2025 · Mar 31, 2025 $9.36M
Current Assets Q1 2025 · Dec 31, 2024 $11.14M
Total Assets Q1 2025 · Mar 31, 2025 $10.33M
Total Assets Q1 2025 · Dec 31, 2024 $12.28M
Shares Diluted Q1 2025 · Mar 31, 2024 6.67M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$2.32M
Stockholders Equity Q1 2025 · Mar 31, 2024 $14.5M
Stockholders Equity Q1 2025 · Dec 31, 2023 $10M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.33
Eps Basic Q1 2025 · Mar 31, 2024 −$0.33
Sga Expense Q1 2025 · Mar 31, 2024 $3.09M
Rd Expense Q1 2025 · Mar 31, 2024 $1.06M
Net Income Q1 2025 · Mar 31, 2024 −$2.22M
Operating Income Q1 2025 · Mar 31, 2024 −$4.11M
Gross Profit Q1 2025 · Mar 31, 2024 $35K
Revenue Q1 2025 · Mar 31, 2024 $35K